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Abstract
Recent studies have shown that mtDNA background could affect the clinical expression of Leber hereditary optic
neuropathy (LHON). We analyzed the mitochondrial DNA (mtDNA) variation of 304 Chinese patients with m.11778G.A
(sample #1) and of 843 suspected LHON patients who lack the three primary mutations (sample #2) to discern mtDNA
haplogroup effect on disease onset. Haplogroup frequencies in the patient group was compared to frequencies in the
general Han Chinese population (n=1,689; sample #3). The overall matrilineal composition of the suspected LHON
population resembles that of the general Han Chinese population, suggesting no association with mtDNA haplogroup. In
contrast, analysis of these LHON patients confirms mtDNA haplogroup effect on LHON. Specifically, the LHON sample
significantly differs from the general Han Chinese and suspected LHON populations by harboring an extremely lower
frequency of haplogroup R9, in particular of its main sub-haplogroup F (#1 vs. #3, P-value=1.46610
217, OR=0.051, 95%
CI: 0.016–0.162; #1 vs. #2, P-value=4.44610
217, OR=0.049, 95% CI: 0.015–0.154; in both cases, adjusted P-value ,10
25)
and higher frequencies of M7b (#1 vs. #3, adjusted P-value=0.001 and #1 vs. #2, adjusted P-value=0.004). Our result
shows that mtDNA background affects LHON in Chinese patients with m.11778G.A but not suspected LHON. Haplogroup
F has a protective effect against LHON, while M7b is a risk factor.
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Introduction
The three primary mutations (m.3460G.A in the MT-ND1
gene, m.11778G.A in the MT-ND4 gene, and m.14484T.Ci n
the MT-ND6 gene) on mitochondrial DNA (mtDNA) have been
identified to be the essential factors for Leber hereditary optic
neuropathy (LHON, OMIM 535000). It is estimated that over
95% of LHON patients have one of the three primary mutations
[1–4]. Despite decades of extensive study on LHON, several
enigmas remain unresolved. Previous studies suggested that
incomplete penetrance and gender bias in the clinical expression
of LHON were modulated by many factors, such as mtDNA
background, nuclear genes and environmental factors [5–11].
By way of replicating the same findings in different and
independent cohorts, it has been well established in European
LHON patients that haplogroups J2, J1 and K increase the risk of
blindness in patients with m.11778G.A, m.14484T.C and
m.3460G.A, respectively, and haplogroup H is suggested to be a
protective factor for LHON patients with m.11778G.A [5,12–
14]. Our previous study of Chinese families with m.11778G.A
showed that haplogroup M7b192 could increase the risk of vision
loss but haplogroup M8a might produce a protective effect [15].
However, frequencies of haplogroups M7b192 and M8a are not
significantly altered in LHON pedigrees compared to the normal
controls despite their apparent background effect on the
penetrance [15]. This pattern is quite different from that of
European patients, in which there is an internal consistency of the
haplogroup association, namely, haplogroup J is present at an
increased frequency in LHON families with m.11778G.A and
m.14484T.C, and subdivisions of this haplogroup show increased
penetrance [5]. Dissecting haplogroups in European LHON
families have shown that the increased frequency of J was indeed
due to an increased frequency of two specific nested sub-clades of J
(one deriving from J1 and another deriving from J2) [5,14].
Insufficient sampling (limited statistical power), and/or potential
population stratification may account for the lack of internal
consistency in our observation [15].
Besides the LHON patients with the primary mutations, there
are many suspected LHON patients expressing LHON clinical
features but carrying none of the three primary mutations [16].
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with suspected LHON has not been well examined. Rare
pathogenic mutations, e.g. m.3635G.A, might account for the
disease expression in a very small portion of these patients (Ref.
[17,18] and references therein). The MT-ND1 and MT-ND6 genes
were found to be mutational hotspots for LHON patients without
the three primary mutations in European populations [19,20].
Similarly, we found that the MT-ND1 and MT-ND5 genes are
mutational hotspots in Chinese suspected LHON patients with a
family history but lacking the three primary mutations [21].
Whether there is an effect of mtDNA background on suspected
LHON has not been tested so far.
In order to further verify the mtDNA haplogroup effect on
LHON and to discern the potential effect of mtDNA background
in cases of suspected LHON, we dissected the matrilineal pool of
304 LHON samples with m.11778G.A and 843 suspected
LHON samples lacking the three primary mutations. We further
sequenced four complete M7b mtDNA genomes and evaluated
haplogroup-specific genetic variants that may be relevant for the
haplogroup association with LHON. Our study provided an
updated profile for the effect of mtDNA background on LHON in
Chinese populations.
Materials and Methods
Ethics statement
Written informed consents conforming to the tenets of the
Declaration of Helsinki were obtained from each participant prior
to the study. The institutional review boards of the Zhongshan
Ophthalmic Center and the Kunming Institute of Zoology
approved this study.
Patients
The patients received ophthalmological examinations at the
Pediatric and Genetic Clinic of the Eye Hospital, Zhongshan
Ophthalmic Center and/or local medical centers, and were
categorized according to the expression of LHON clinical features
(e.g. painless, acute or sub-acute vision deterioration without
apparent reasons). LHON patients with primary mutation
m.14484T.C or m.3460G.A were reported elsewhere [22,23]
and were not discussed in this study. 175 LHON patients with
m.11778G.A had a family history and were described in our
previous study [15]; these patients were reanalyzed with the new
samples in this study. LHON patients with both m.11778G.A
and m.593T.C (n=14) and suspected LHON patients with
m.593T.C (n=12) were discussed in a separate paper [24].
Patients without the three primary mutations of LHON were
simply regarded as patients with suspected LHON, despite that
this grouping included a very small proportion of LHON patients
that were caused by other rare primary LHON mutations. Blood
samples were collected from patients in vacuum tubes containing
EDTA. For some cases, blood samples were collected on filtered
papers.
Screening of primary LHON mutations, sequencing the
mtDNA control region and complete genome
The PCR-single strand conformation polymorphism (PCR-
SSCP) and allele specific PCR (AS-PCR) methods were jointly
used to detect the three primary mutations as previously described
[25]. The presence of the three primary mutations in the patients
was independently screened in Kunming using method described
by Bi et al. [26]. The mtDNA control region sequence of each
patient was amplified by using primer pair (L15594: 59-CG-
CCTACACAATTCTCCGATC-39 and H901: 59-ACTTGGGT-
TAATCGTGTGACC-39) and the following PCR condition: one
pre-denaturation cycle at 94uC for 5 min; 30 cycles at 94uC for
30 sec, 52uC for 30 sec, 72uC for 2 min; and one extension cycle
at 72uC for 10 min. The PCR products were purified and
sequenced by sequencing primers, which were used in our
previous study [27], on a 3730 DNA analyzer (Applied
Biosystems). Each sample was sequenced for an approximate
1.4 kb fragment (mtDNA regions 16033–16569 and 1–850;
numbering according to the revised Cambridge reference
sequence (rCRS) [28]) which cover the mtDNA control region,
the MT-TF gene and part of the MT-RNR1 gene. We determined
the entire mtDNA sequences for four LHON patients (Fig. S1)
belonging to haplogroup M7b192 using the same procedure and
condition described in our previous study [27]. Novelty and
potential pathogenicity for those non-synonymous private variants
in these lineages were analyzed using the same method reported
by Bandelt et al. [29].
mtDNA haplogroup classification and statistical analysis
The sequences were compared with the rCRS [28] and the
variants in each mtDNA sequence were recorded and were further
checked by using the MitoTool (www.mitotool.org) [30]. We
classified each sample based on the haplogroup motifs that were
identified according to the PhyloTree (http://www.phylotree.org;
mtDNA tree Build 9, 20 Jun 2010) [31]. For samples which could
not be unambiguously determined by the mtDNA control region
sequence variants, PCR- restriction fragment length polymor-
phism (RFLP) analysis for specific coding region variant(s) was
performed, e.g. a check of 25176AluI was performed to confirm
haplogroup D status.
We first compared the matrilineal composition of suspected
LHON patients (n=843) to 1,689 pooled Han Chinese mtDNAs
from the general populations (Table S1), to discern the potential
effect of mtDNA background on the onset of suspected LHON.
Under the null hypothesis that the suspected LHON patients had
a similar matrilineal composition as the pooled Han Chinese, the
suspected LHON patients could be used as a second control group
for comparison to the LHON patients. We then compared the
newly obtained 304 LHON patients with m.11778G.A to the
suspected LHON samples and the pooled Han Chinese samples,
respectively, to discern the mtDNA haplogroup background effect
on LHON and to verify the pattern as observed in our previous
studies based on limited sample sizes [15]. We next pooled the
newly obtained LHON patients (n=304) with the reported LHON
patients (n=175; [15]). Combining these two different datasets
provide more statistical power than the strategy of analyzing both
data sets separately (Methods S1) [32].
Pearson’s chi-square test with a one degree of freedom was used
to assess the significance of the differences observed in haplogroup
frequencies between cases and controls. The Fisher Exact test (two
tailed) was applied to those cases with cell counts below five. A
permutation test was used to address the issue of multiple testing in
haplogroup association test; 100,000 permutations were used in all
comparisons. The statistical package SPSS (version 15.0) and Stata
v.8 (http://www.stata.com) were used for all the computations;
adjusted P-values below 0.05 were considered to be statistically
significant.
Results
Patient features
A total of 1,322 unrelated subjects collected from different
provinces in China were enrolled in the current analysis based on
the availability of DNA after the initial primary mutation
mtDNA Haplogroup and LHON
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mutation m.11778G.A (including 175 samples reported in our
previous study [15] and 304 samples newly sequenced) and 843
suspected LHON patients who expressed clinical features but did
not harbor any of the three primary mutations. Only one out of
479 patients had the heteroplasmic mutation m.11778G.A. The
overall frequency of patients with heteroplasmic mutation
m.11778G.A was thus very low (0.21%; 1/479) in these Chinese
patients based on the limitation of detection sensitivity of our
approach. The mtDNA control region sequence variations for
each patient are listed in the online Tables S2 and S3, and the
sequences can be retrieved from GenBank under the Accession
Numbers HM632037–HM632340 (for 304 LHON patients with
m.11778G.A) and HM632341–HM633183 (for 843 suspected
LHON patients).
mtDNA Haplogroup distribution in patients with
suspected LHON
We first dissected the matrilineal genetic components in the
suspected LHON (sample #2) and compared to the pooled Han
Chinese from the general populations (sample #3, n=1,689). As
shown in Table 1 and Fig. 1, the overall matrilineal composition of
the 843 suspected LHON patients resembled that of the pooled
Han Chinese. There was no statistically significant difference for
any of the haplogroup classes between the two populations.
Therefore, the suspected LHON sample, despite of its miscella-
neous nature of the disease, could be used as the second
independent control sample to compare with LHON patients
with m.11778G.A in the subsequent analyses.
mtDNA Haplogroup distribution in LHON patients with
m.11778G.A
To compare with the pattern that was reported in our previous
studies based on limited number of patients [15], we treated the
newly obtained 304 LHON patients as an independent sample
(sample #1) and compared to the two control population groups.
We found that haplogroups R9 (including its subhaplogroups F,
F1, F1a) and M7b presented remarkable differences between the
LHON patients and the controls after adjusting for multiple test
(Tables 2 and 3). The LHON sample significantly differs from the
Table 1. Haplogroup frequencies and Pearson’s chi-square test in 843 patients with suspected LHON and 1,689 Han Chinese from
the general populations.
Haplogroup Suspected LHON Pooled Han Chinese
a P-value
b
Adjusted
P-value
c OR 95% CI
A 31 92 0.064 0.686 0.663 0.437–1.004
B4 126 196 0.021 0.314 1.339 1.052–1.703
B5 54 94 0.448 1.000 1.161 0.822–1.640
C 35 51 0.172 0.969 1.391 0.897–2.157
D4 115 252 0.423 1.000 0.901 0.710–1.143
D5 32 88 0.139 0.934 0.718 0.475–1.085
R9
d 164 305 0.394 0.999 1.413 0.804–2.483
F 143 274 0.677 1.000 1.055 0.845–1.317
F1 99 193 0.229 0.991 1.175 0.903–1.530
F1a 71 132 0.281 0.997 1.165 0.882–1.541
F2 17 48 0.216 0.988 1.421 0.812–2.487
F2a 16 22 0.246 0.994 1.466 0.766–2.806
F3 12 15 0.216 0.988 1.612 0.751–3.458
F3a 12 13 0.117 0.887 1.862 0.846–4.098
F4 7 8 0.270 0.996 1.759 0.636–4.868
G 31 71 0.598 1.000 0.870 0.566–1.338
M10 14 35 0.579 1.000 0.798 0.427–1.492
M12 8 4 0.031 0.436 4.036 1.212–13.441
M7b 59 119 1.000 1.000 0.993 0.718–1.372
M7c 32 54 0.504 1.000 1.195 0.765–1.865
M8a 27 63 0.575 1.000 0.854 0.540–1.351
M9a 11 29 0.539 1.000 0.757 0.376–1.522
N9a 33 62 0.847 1.000 1.069 0.695–1.645
R11 5 10 1.000 1.000 1.002 0.341–2.940
Y 7 16 0.944 1.000 0.876 0.359–2.136
Z 21 50 0.585 1.000 0.837 0.500–1.404
aPooled Han Chinese were from reported populations (see Table S1 for more information).
bTwo tailed Fisher exact test was applied instead of a Pearson chi-square test in cases containing cell counts below five.
cAdjusted P-value: adjustment of P-values was carried out with a permutation-based approach; number of permutations=100,000; OR (95% CI): Odds Ratio (95%
Confidence Interval).
dNote that haplogroup F is a sub-haplogroup of haplogroup R9 and therefore the number of F mtDNAs are also included here.
doi:10.1371/journal.pone.0027750.t001
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harboring an extremely lower frequency of haplogroup R9 (#1
vs. #3, P-value=7.62610
219, OR=0.061, 95% CI: 0.022–0.164;
#1 vs. #2, P-value=5.19610
219, OR=0.055, 95% CI: 0.020–
0.150; in both cases, adjusted P-value ,10
25), in particular of its
main sub-haplogroup F (#1 vs. #3, P-value=1.46610
217,
OR=0.051, 95% CI: 0.016–0.162; #1 vs. #2, P-val-
ue=4.32610
217, OR=0.049, 95% CI: 0.015–0.154; in both
cases, adjusted P-value ,10
25) and higher frequencies of M7b (#1
vs. #3, P-value=7.00610
25, adjusted P-value=0.001 and #1 vs.
#2, P-value=3.23610
24, adjusted P-value=0.004). Distribution
of the other haplogroups had no statistical difference between the
two comparisons after adjustment of P-values.
We further pooled the newly analyzed LHON patients with the
previously reported LHON patients [15] as one population for
comparison, to increase the power of the statistical test [32]. The
dissection of matrilineal genetic components in the enlarged
LHON population [479 LHON patients with m.11778G.A
(sample #4)] and comparison to the two control groups [suspected
LHON (sample #2) and pooled Han Chinese from the general
populations (sample #3)] revealed several interesting yet impor-
tant features (Fig. 1 and Tables S4 and S5). First, haplogroups
M7b (#4 vs. #3, adjusted P-value=0.018; #4 vs. #2, adjusted P-
value=0.047) and possibly D4 (#4 vs. #3, adjusted P-
value=0.085; #4 vs. #2, adjusted P-value=0.031) are both
more prevalent in patients with LHON than in the general Han
Chinese group. Most of LHON patients with m.11778G.A
belonging to haplogroup M7b could be further classified into
M7b192 (77.19%, 44/57). Second, haplogroup R9, and more
specifically, its sub-haplogroup F has a strikingly lower frequency
in LHON patients with m.11778G.A than in the other two
control populations (#4 vs. #3, nominal P-value=1.999610
224,
adjusted P-value ,10
25; #4 vs. #2, nominal P-val-
ue=9.133610
223, adjusted P-value ,10
25). This significance is
still strongly maintained for several F sub-haplogroups (F, F1, F1a),
as also indicated when analyzing the newly sequenced LHON
patients (Tables 2 and 3) and the reported LHON patients with
m.11778G.A in our previous study (Ref. [15] and references
therein) (Tables S6 and S7), separately.
Complete mtDNA tree for LHON patients belonging to
haplogroup M7b192
In order to further evaluate the effect of the haplogroup-
specific variants that account for the haplogroup association with
LHON, we determined four M7b complete mtDNAs (GenBank
accession numbers JN645818–JN645821), and analyzed these
sequences with those from published sources [24]. Five private
variants (including four non-synonymous and one rRNA variant)
were found in the four patients, but none of these variants (with
the exception of m.8999T.C [p.V158A]) were conserved
according to the evolutionary analysis performed by the
MitoTool web server (Table 4). Two of these private variants
(m.13105A.G and m.14978A.G) were reported as haplogroup-
specific variants for other haplogroups. Interestingly,
m.6228C.T (p.L109F) in patient Le777 and m.13105A.G
(p.I257V) in patient Le666 were previously reported in LHON
patients belonging to haplogroup M7b192 [15]. We presented
sequence variants in each mtDNA in a classification tree
following our previous strategy [15] (Fig. 2). The newly
determined M7b sequences indicated two novel clades within
M7b1, which were defined by m.13105A.G and m.6228C.T,
respectively. We counted the number of private variants that
were located in the terminal branches of the phylogenetic tree in
each of the 13 mitochondrial DNA encoding genes in 12 LHON
patients sequenced in this study and our previous study [15], and
compared to that of 69 reported complete mtDNAs from the
general populations (refer to [21] and references therein). There
was no difference regarding the occurrence of private non-
synonymous (NS) and synonymous (S) substitutions between the
LHON patients and controls from the general populations; note
that the sample size was very limited and this result should be
treated with caution (Table S8).
Figure 1. mtDNA haplogroup distribution frequency of different cohorts of LHON patients with m.11778G.A and control samples.
Detailed information for the newly sequenced LHON patients with m.11778G.A (sample #1, n=304), reported LHON patients with m.11778G.Ai n
our previous study (sample #5, n=175; Ref. [15]), pooled LHON patients (sample #4, n=479), suspected LHON patients (sample #2, n=843) and the
reported Han Chinese from the general populations (sample 3, n=1,689; Table S1) are listed in Tables 2 and 3 and Tables S4, S5, S6, S7. Haplogroup
R9 contains samples belonging to haplogroup F and its subhaplogroups. We lumped together all these haplogroups that occurred in less than five
individuals per haplogroup as others.
doi:10.1371/journal.pone.0027750.g001
mtDNA Haplogroup and LHON
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In recent years, many studies reported that mtDNA background
affects the expression of human disorders [33–37], although some
positive findings could respond to false positives [38]. Among these
studies, LHON is probably the most extensively studied disease
that has been reported to be modulated by mtDNA haplogroups
[5,12–15]. In this study, we analyzed 479 unrelated LHON
samples with m.11778G.A (including 175 LHON patients
reported in our previous study [15] and 304 patients newly
sequenced) and 843 suspected LHON patients without the three
primary mutations, with the aim of primarily addressing the
following questions: (1) does mtDNA haplogroup background
contribute to the suspected LHON? (2) will the enlarged LHON
patients with m.11778G.A discern the internal consistency of the
haplogroup association of LHON penetrance? Dissecting the
matrilineal components of the enlarged sample size of LHON
patients with m.11778G.A and the suspected LHON patients did
provide new insightful information to both questions.
In contrast to the pattern that was observed in the LHON
patients with m.11778G.A [15], the overall matrilineal compo-
sition of the suspected LHON patients resembles that of the
pooled Han Chinese, showing no evident effect from mtDNA
background (Fig. 1 and Tables 1, 2, 3). This result was not
surprising, as the suspected LHON cohort was quite heteroge-
neous and might be caused by nuclear gene defects, as well as,
some rare mtDNA pathogenic mutations. Indeed, we analyzed
some of these patients and identified mutations in the OPA1 gene,
suggesting that these patients should be classified as autosomal
dominant optic atrophy (ADOA; authors’ unpublished data).
Nonetheless, the suspected LHON population could be used as a
suitable control population for the LHON patients carrying
m.11778G.A. In addition, both LHON carriers and none
carriers of m.11778G.A were collected in the same geographic
origin, a fact that helps to prevent the undesirable effects of
population stratification in inflating type I error.
A direct comparison of the frequencies of the matrilineal
components between the LHON population and the suspected
LHON population or between the LHON population and the
pooled Han Chinese from the general populations yields
meaningful information on the mtDNA background effect on
LHON. Haplogroup M7b192, which was found to increase vision
loss risk in the presence of m.11778G.A [15], had a significantly
higher occurrence in LHON patients with this mutation than in
patients with suspected LHON or in Han Chinese from the
general populations (Tables 2 and 3 and Tables S4 and S5). This
Table 2. Haplogroup frequencies and Pearson’s chi-square test in 304 LHON patients with m.11778G.A and 843 patients with
suspected LHON.
Haplogroup LHON Suspected LHON P-value
a Adjusted P-value
b OR 95% CI
A 6 31 0.150 0.931 0.527 0.218–1.277
B4 43 126 0.735 1.000 0.938 0.645–1.363
B5 21 54 0.761 1.000 1.084 0.643–1.827
C 14 35 0.738 1.000 1.114 0.591–2.101
D4 58 115 0.023 0.304 1.493 1.055–2.112
D5 13 32 0.712 1.000 1.132 0.586–2.187
R9
c 4 164 5.190610
219 ,10
25 0.055 0.020–0.150
F 3 143 4.319610
217 ,10
25 0.049 0.015–0.154
F1 2 99 1.003610
211 ,10
25 0.050 0.012–0.203
F1a 1 71 6.614610
29 ,10
25 0.036 0.005–0.259
F2 0 17 9.725610
23 0.141 0.731 0.706–0.757
F3 1 12 0.203 0.979 0.229 0.030–1.765
F3a 1 12 0.203 0.979 0.229 0.030–1.765
F4 0 7 0.200 0.977 0.733 0.708–0.759
G 14 31 0.475 1.000 1.265 0.663–2.411
M10 13 14 0.010 0.144 2.645 1.229–5.694
M12 0 8 0.119 0.872 0.733 0.708–0.759
M7b 42 59 3.233610
24 0.004 2.130 1.400–3.241
M7c 15 32 0.391 0.999 1.315 0.702–2.465
M8a 11 27 0.729 1.000 1.135 0.556–2.316
M9a 9 11 0.059 0.631 2.308 0.947–5.624
N9a 12 33 0.980 1.000 1.009 0.514–1.979
R11 0 5 0.333 0.999 0.734 0.709–0.760
Y 5 7 0.232 0.989 1.997 0.629–6.340
Z 8 21 0.894 1.000 1.058 0.464–2.414
aTwo tailed Fisher exact test was applied instead a Pearson chi-square test in cases containing cell counts below five.
bAdjusted P-value: adjustment of P-values was carried out with a permutation-based approach; number of permutations=100,000; OR (95% CI): Odds Ratio (95%
Confidence Interval).
cNote that haplogroup F is a sub-haplogroup of haplogroup R9 and the number of F mtDNAs are also included here.
doi:10.1371/journal.pone.0027750.t002
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Haplogroup LHON Pooled Han Chinese
a P-value
b Adjusted P-value
c OR 95% CI
A 6 92 0.010 0.144 0.350 0.152–0.806
B4 43 196 0.210 0.981 1.255 0.880–1.790
B5 21 94 0.355 1.000 1.259 0.772–2.055
C 14 51 0.152 0.948 1.551 0.847–2.838
D4 58 252 0.065 0.673 1.344 0.980–1.844
D5 13 88 0.494 1.000 0.813 0.448–1.474
R9
d 4 304 7.621610
219 ,10
25 0.061 0.022–0.164
F 3 274 1.461610
217 ,10
25 0.051 0.016–0.162
F1 2 193 2.822610
212 ,10
25 0.051 0.013–0.208
F1a 1 132 5.356610
29 ,10
25 0.039 0.005–0.280
F2 0 48 7.125610
24 0.012 0.844 0.828–0.860
F3 1 15 0.492 1.000 0.368 0.049–2.799
F3a 1 13 0.708 1.000 0.425 0.055–3.265
F4 0 8 0.616 1.000 0.847 0.831–0.863
G 14 71 0.750 1.000 1.100 0.612–1.978
M10 13 35 0.021 0.288 2.111 1.104–4.039
M12 0 4 1.000 1.000 0.847 0.831–0.863
M7b 42 119 6.669610
25 0.001 2.115 1.453–3.078
M7c 15 54 0.127 0.908 1.572 0.875–2.822
M8a 11 63 0.925 1.000 0.969 0.505–1.861
M9a 9 29 0.144 0.936 1.746 0.818–3.727
N9a 12 62 0.814 1.000 1.078 0.574–2.026
R11 0 10 0.376 1.000 0.847 0.831–0.863
Y 5 16 0.273 0.995 1.749 0.636–4.809
Z 8 50 0.754 1.000 0.886 0.416–1.888
aPooled Han Chinese were from reported populations (see Table S1 for more information).
bTwo tailed Fisher exact test was applied instead a Pearson chi-square test in cases containing cell counts below five.
cAdjusted P-value: adjustment of P-values was carried out with a permutation-based approach; number of permutations=100,000; OR (95% CI): Odds Ratio (95%
Confidence Interval).
dNote that haplogroup F is a sub-haplogroup of haplogroup R9 and the number of F mtDNAs are also included here.
doi:10.1371/journal.pone.0027750.t003
Table 4. Private non-synonymous and mt-rRNA variants in four Chinese LHON patients with m.11778G.A and a haplogroup
status of M7b192.
Sample Haplogroup
Nucleotide variant
(Amino acid change) Gene
Conservation
Index
a
Reported
b
(population context)
Reported
b
(disease context)
Haplogroup
specific variant
c
Le95 M7b2 m.8999T.C (p.V158A) MT-ATP6 1.000 Yes No No
m.866A.G MT-RNR1 0.256 Yes No No
Le666 M7b1 m.13105A.G (p.I257V) MT-ND5 0.256 Yes Yes L5c, L3b, L3e2a, etc.
Le777 M7b1 m.6228C.T (p.L109F) MT-CO1 0.140 Yes Yes No
Le978 M7b19294 m.A14978G (p.I78V) MT-CYB 0.651 Yes Yes C7a1
aThe evolutionary conservation analysis was performed by comparing human mtDNA (GenBank accession no. J01415) to 43 different primate species by using the
MitoTool (http://www.mitotool.org) [30]. A conservation index of 1 for certain variant means that this position is conserved in all species considered for comparison.
bWeb and dataset based searches were performed on September 5, 2011, following the same strategy described in our previous study [29] (e.g. both ‘G6249A mtDNA’
and ‘m.6249G.A mtDNA’ were queried).
cThe column ‘‘Haplogroup specific variant’’ refers to the presence of the corresponding variant in the world mtDNA phylogenetic tree displayed at http://www.
phylotree.org/tree/main.htm (mtDNA tree Build 12; 20 Jul 2011) [31]. We listed the haplogroup name if it was characterized by the private variants identified in our
newly generated M7b sequences.
doi:10.1371/journal.pone.0027750.t004
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association of haplogroup M7b192 with clinical expressions of
LHON, as predicted by our previous study [15]. Note that in our
previous study [15], the sample size for the control Han Chinese
population was relatively small (n=408) and this would bias the
comparison for certain haplogroup. This defect had been
corrected by including more Han Chinese samples from the
general populations (n=1,689) in the current analysis (Tables S6
and S7). As shown in Tables S2 and S3, most of the mtDNAs
belonging to M7 and its subhaplogroups carry different control
region profiles, indicating no close maternal relationship between
these carriers; the different frequencies observed between cohorts
are unlikely to be caused by close kinship. Analysis of the complete
mtDNA sequence variation in those LHON patients belonging to
M7b further supported our previous result that variant
m.12811T.C would account for the haplogroup association with
Figure 2. Classification tree of M7b complete mtDNA sequences, plus the revised Cambridge reference sequence (rCRS) [28]. Five
Chinese LHON mtDNAs (including Le53 (GenBank accession number JF896798) which was reported in our recent study [24]) belonged to haplogroup
M7b192 were analyzed. The length polymorphisms of the C-tracts in region 303–309 were not considered. Mutations on each uninterrupted branch
segment are listed in an arbitrary order. Recurrent mutations are underlined. The synonymous and non-synonymous coding-region variants in each
mtDNA are denoted by ‘‘/s’’ and ‘‘/ns’’, respectively. Variants in the rRNA genes and tRNA genes are denoted by ‘‘/r’’ and ‘‘/t’’, respectively.
doi:10.1371/journal.pone.0027750.g002
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for the overall increased risk for visual loss for pedigrees belonging
to haplogroup M7b192.
On the other hand, haplogroup M8a was found to reduce the
clinical penetrance of mutation m.11778G.A in Chinese families
in our previous study [15]. However, even with increased sample
size of LHON patients, there was no indication, as it was expected,
of a reduced frequency of M8a in LHON patients relative to
control populations.
Consistent with the previous observations [15], haplogroup D4
has a substantially higher frequency in the LHON patients (for 304
new patients, 58/304=19.08%; for pooled 479 patients, 98/
479=20.50%) than in patients with suspected LHON (13.64%,
115/843) or in the pooled Han Chinese population (14.92%, 252/
1689), though the adjusted P-value is not statistically significant
(but marginal for pooled samples) between LHON patients and
pooled Han Chinese. Because more than half of the LHON
patients analyzed in this study were sporadic cases and we lacked
the detailed clinical information for some families with self-
reported disease history, we were unable to perform a correlation
analysis to discern the effect of haplogroup D4 on the clinical
expression of LHON. We failed to discern such an effect in our
previous analysis for LHON families with m.11778G.A (Ref.
[15] and references therein). Haplogroup D4 is defined by a string
of non-synonymous variants (m.5178C.A in the MT-ND2 gene
and m.8414C.T in the MT-ATP6 gene), synonymous variants
(m.4883C.T in the MT-ND2 gene, m.14668C.T in the MT-
ND6 gene) and one variant (m.3010G.A) in the MT-RNR2 gene.
It is most likely that the non-synonymous variants of haplogroup
D4 might be responsible for the potentially functional effect.
Indeed, variant m.5178C.A had been reported to be associated
with a variety of human disorders [39] and longevity [40], despite
the fact that there was controversy regarding its role in longevity
[41], and the functional assay did not support the notion that this
variant could alter mitochondrial matrix pH and intracellular
calcium dynamics [42]. The exact role of haplogroup D4 in
LHON needs further study.
Haplogroup F was very rare in the LHON patients (for 304
new patients, 3/304=0.99%; for pooled 479 patients, 6/
479=1.25%), compared with its occurrence in the pooled Han
Chinese from the general populations (274/1689=16.22%) and
in the suspected LHON patients (143/843=16.96%). This result
again confirmed the observation in our previous study [15] and a
recent study in LHON patients from Thailand [10], in which an
extremely low frequency of haplogroup F (including its
subhaplogroups) was observed in LHON patients with
m.11778G.A. Although the confounding effect of population
stratification cannot be fully disregarded, the clear-cut different
frequency of haplogroup F in two independent Chinese LHON
patient cohorts (patients newly determined in this study and
reported in our previous study [15]; Tables 2 and 3, Tables S6
and S7) with respect to the two independent control groups
(suspected LHON patients plus the general Han Chinese) is so
pronounced that it is reasonable to consider an alternative
hypothesis that would involve haplogroup F as a protective factor
in LHON patients. Because only six patients with m.11778G.A
belong to haplogroup F in the LHON patients and half of them
were sporadic, we could not estimate its potential effect on the
clinical expression of LHON and analysis of the complete
mtDNA sequence of some of these subjects yielded no insightful
information [15]. Intriguingly, we also noticed a very low
prevalence of F lineages (1.92%; 1/52) in LHON subjects with
m.14484T.C in our recent study [23]. The exact reason for the
extremely low frequency of F lineages in LHON patients with
m.11778G.A or m.14484T.C remains enigmatic. Notably,
haplogroup F is one of the sub-clades of haplogroup R9, and R9
showed evidently lower frequency in LHON patients than in the
two control samples (Tables 2 and 3, Tables S4, S5, S6, S7), so
the ancient genetic variants of haplogroup R9 might contribute to
the pathogenesis of LHON patients. Variant m.13928G.Cw a s
the only non-synonymous nucleotide change at the basal branch
level of haplogroup R9 and caused serine to threonine at position
531 of the MT-ND5 protein, but this variant did not alter the
hydrophobicity significantly and occurred multiple times in
different populations and haplogroup backgrounds (cf. www.
phylotree.org). Similar to mtDNA variant m.12811T.Cw h i c h
has been considered as the cause for the increased risk of M7b192
[15] and occurred in worldwide regions, the conservation and the
hydrophobicity of m.13928G.C did not prove itself to be the
possible pathogenic mutation, although recent studies showed
that ancient variation may influence mtDNA replication and
transcription [43] or contribute to cellular physiological changes
in the presence of the primary mutations [44]. The deletion of
adenine at position 249 is a characteristic variant of haplogroup F
and other Asian haplogroups CZ, M31a1 and M36d1 [31].
Variant m.249delA was located in the mtTF1 binding site (MT-
TFX or TFAM) which binds with mtTF and controls mtDNA
transcription [45]. Some single base changes within this region
have been identified to alter protein binding efficiency [43].
Whether m.249delA could affect the efficiency of mtDNA
transcription remains unclear.
Population stratification could in part explain the results
obtained in the present study. Monitoring population stratification
is complex in mtDNA studies, but the use of two control groups, as
performed in this study, helps to prevent its undesirable
consequences in case-control studies. On the other hand, whether
treating the newly analyzed 304 LHON patients with
m.11778G.A and the reported LHON patients in our previous
study [15] as independent samples, or pooled these new patients
with the previously reported LHON patients [15] as an enlarged
sample, we could get consistent findings for a lower frequency of
the nested haplogroups R9, F, F1, and F1a. Therefore, we believe
that different distribution frequencies of these haplogroups in
LHON patients and control populations were biologically
meaningful and might be shaped by the selection effect during
the past.
One limitation of the current study is that we lacked detailed
clinical information for these patients newly sequenced in this
study (most of these patients were collected more than five years
ago and there was no follow-up information), we could not
perform a systematic estimation for LHON penetrance, disease
severity and propensity to spontaneous recovery of visual acuity, as
well as, their correlation with mtDNA genetic background. In
future study, we will attempt to collect all detailed clinical data for
each newly recruited patient and fulfill the task.
In summary, analysis of more newly collected LHON patients
with m.11778G.A further supports the pattern that was observed
in our previous studies [15], in that a significantly higher
prevalence of haplogroups M7b and a strikingly low occurrence
of haplogroup F have been confirmed. The higher frequency of
M7b in patients with m.11778G.A than in control samples
provides evidence for the internal consistency of association of
haplogroup M7b192 with clinical expression of LHON. There was
no evident effect of mtDNA background on Chinese patients with
suspected LHON. Future studies could assist in providing further
support to the present findings and provide new clues on the
molecular mechanism by which a particular mtDNA background
could influence clinical expression of LHON.
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sequence variation in our previous study [15].
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